Karolinska Institutet (KI) Innovations have partnered with Medicon Valley Alliance member AbbVie, a global biopharmaceutical company, to launch a Scandinavia Golden Ticket
designed to accelerate companies
developing novel, transformational therapies and innovations for immunology, oncology, neuroscience, eye care and medical aesthetics.
The Golden Ticket programme is designed to support innovative early-stage biotech companies in their efforts to accelerate the development of new therapies to improve human health. The programme offers the opportunity to secure one year of funding for lab space and mentorship and scientific expertise to support the company’s development.
The AbbVie Scandinavia Golden Ticket program offers one year of access to:
- Lab space, with access to research and office facilities and services for 1-2 scientists, provided by KI Innovations in Stockholm.
- Mentorship and business coaching from KI Innovations throughout the year.
- Tailored support from AbbVie’s international researchers and mentors.
- Exclusive access to AbbVie and KI Innovations networks during the year, with the opportunity for future collaboration.
Learn more about
eligibility and how to apply as an early-stage Life Science biotech Startup on the website of Karolinska Institutet. The call closes January 31st.
